Keyphrases
Adjuvant Chemotherapy
81%
Confidence Interval
63%
Chemotherapy
57%
Meningioma
53%
Breast Cancer
50%
Elderly Patients
41%
Radiation Therapy
41%
Tumor
40%
Hazard Ratio
35%
Surveillance Epidemiology
34%
Women with Breast Cancer
30%
United States
29%
Elderly Women
28%
Early Breast Cancer
27%
NF2 Gene
27%
Mammographic Density
27%
Chemotherapy Initiation
27%
Odds Ratio
25%
Adjuvant Radiotherapy
25%
Racial Disparities
24%
Colon Cancer
23%
NF-2
23%
Tumor Size
23%
Breast Reconstruction
23%
Screening Mammography
22%
Medicare Database
22%
Doxorubicin
22%
Inflammatory Bowel Disease
21%
Progression-free Survival
21%
Overall Survival
21%
Robot-assisted Laparoscopic Radical Prostatectomy
21%
Poor Survival
20%
Mutation Status
19%
Crohn's Disease
19%
Atypical Meningioma
19%
Cancer Clinical Trials
18%
Recurrent Meningioma
18%
Stage III Colon Cancer
18%
Cardiac Toxicity
18%
Cardiac Risk
18%
Hepatocellular Carcinoma
18%
Surgeon Characteristics
18%
Advanced Ovarian Cancer
18%
Cancer Adjuvant
18%
Celiac Disease
18%
Prostate Cancer
18%
Recurrence Rate
18%
Older Patients
16%
African American
16%
Prostate Size
16%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
73%
Chemotherapy
67%
Malignant Neoplasm
62%
Radiation Therapy
51%
Adjuvant Chemotherapy
50%
Meningioma
45%
Medicare
36%
Mammography
30%
Disease
29%
Elderly Patient
29%
Biopsy Technique
28%
Surveillance, Epidemiology, and End Results
28%
Hazard Ratio
24%
Adjuvant Radiotherapy
23%
Racial Disparity
22%
Odds Ratio
22%
Clinical Trial
22%
Prostatectomy
20%
Prostate Cancer
19%
Crohn's Disease
19%
Ulcerative Colitis
19%
Socioeconomic Status
19%
Recurrent Disease
19%
Dysplasia
18%
COVID-19
18%
Ovarian Cancer
18%
Hepatocellular Carcinoma
18%
Cancer Adjuvant Therapy
18%
Surgeon
18%
Colon Carcinoma
18%
Proportional Hazards Model
16%
Comorbidity
16%
Lymph Node
15%
Digital Mammography
15%
Severe Acute Respiratory Syndrome Coronavirus 2
15%
Inflammatory Bowel Disease
15%
Overall Survival
14%
Primary Tumor
14%
Cancer Diagnosis
14%
Bladder Cancer
13%
Transplantation
13%
Adenocarcinoma
12%
Prostate Specific Antigen
12%
Carcinoma
12%
Patient with Inflammatory Bowel Disease
12%
Progression Free Survival
12%
Doxorubicin
11%
Colorectal Carcinoma
10%
Biological Product
10%